• 1
    Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095147.
  • 2
    Sims JE, March CJ, Cosman D, Widmer MB, MacDonald HR, McMahan CJ, et al. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science 1988; 241: 5859.
  • 3
    Sims JE, Acres RB, Grubin CE, McMahan CJ, Wignall JM, March CJ, et al. Cloning the interleukin 1 receptor from human T cells. Proc Natl Acad Sci U S A 1989; 86: 894650.
  • 4
    Greenfeder SA, Nunes P, Kwee L, Labow M, Chizzonite RA, Ju G. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J Biol Chem 1995; 270: 1375765.
  • 5
    Cullinan EB, Kwee L, Nunes P, Shuster DJ, Ju G, McIntyre KW, et al. IL-1 receptor accessory protein is an essential component of the IL-1 receptor. J Immunol 1998; 161: 561420.
  • 6
    Wesche H, Korherr C, Kracht M, Falk W, Resch K, Martin MU. The interleukin-1 receptor accessory protein (IL-1RAcP) is essential for IL-1-induced activation of interleukin-1 receptor-associated kinase (IRAK) and stress-activated protein kinases (SAP kinases). J Biol Chem 1997; 272: 772731.
  • 7
    Wesche H, Resch K, Martin MU. Effects of IL-1 receptor accessory protein on IL-1 binding. FEBS Lett 1998; 429: 3036.
  • 8
    Casadio R, Frigimelica E, Bossu P, Neumann D, Martin MU, Tagliabue A, et al. Model of interaction of the IL-1 receptor accessory protein IL-1RAcP with the IL-1β/IL-1R(I) complex. FEBS Lett 2001; 499: 658.
  • 9
    Burns K, Martinon F, Esslinger C, Pahl H, Schneider P, Bodmer JL, et al. MyD88, an adapter protein involved in interleukin-1 signaling. J Biol Chem 1998; 273: 122039.
  • 10
    Burns K, Clatworthy J, Martin L, Martinon F, Plumpton C, Maschera B, et al. Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. Nat Cell Biol 2000; 2: 34651.
  • 11
    Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 1997; 7: 83747.
  • 12
    Muzio M, Ni J, Feng P, Dixit VM. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 1997; 278: 16125.
  • 13
    Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel DV. TRAF6 is a signal transducer for interleukin-1. Nature 1996; 383: 4436.
  • 14
    Cao Z, Henzel WJ, Gao X. IRAK: a kinase associated with the interleukin-1 receptor. Science 1996; 271: 112831.
  • 15
    McMahan CJ, Slack JL, Mosley B, Cosman D, Lupton SD, Brunton LL, et al. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J 1991; 10: 282132.
  • 16
    Huang J, Gao X, Li S, Cao Z. Recruitment of IRAK to the interleukin 1 receptor complex requires interleukin 1 receptor accessory protein. Proc Natl Acad Sci U S A 1997; 94: 1282932.
  • 17
    Radons J, Gabler S, Wesche H, Korherr C, Hofmeister R, Falk W. Identification of essential regions in the cytoplasmic tail of interleukin-1 receptor accessory protein critical for interleukin-1 signaling. J Biol Chem 2002; 277: 1645663.
  • 18
    Lang D, Knop J, Wesche H, Raffetseder U, Kurrle R, Boraschi D, et al. The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness. J Immunol 1998; 161: 68717.
  • 19
    Symons JA, Young PR, Duff GW. Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1β precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci U S A 1995; 92: 17148.
  • 20
    Bakker AC, Joosten LA, Arntz OJ, Helsen MM, Bendele AM, van de Loo FA, et al. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum 1997; 40: 893900.
  • 21
    Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen–induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti–IL-1α/β, and IL-1Ra. Arthritis Rheum 1996; 39: 797809.
  • 22
    Jensen LE, Whitehead AS. Expression of alternatively spliced interleukin-1 receptor accessory protein mRNAs is differentially regulated during inflammation and apoptosis. Cell Signal 2003; 15: 793802.
  • 23
    Jensen LE, Muzio M, Mantovani A, Whitehead AS. IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein. J Immunol 2000; 164: 527786.
  • 24
    Smeets RL, van de Loo FA, Joosten LA, Arntz OJ, Bennink MB, Loesberg WA, et al. Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis. Arthritis Rheum 2003; 48: 294958.
  • 25
    Smeets RL, van de Loo FA, Joosten LA, Arntz OJ, Bennink MB, Dmitriev IP, et al. Modulation of arthritis through overexpression of soluble interleukin-1 receptor accessory protein (sIL-1RAcP): a novel inhibitor of interleukin-1, distinct from IL-1Ra. Inflamm Res 2003; 52 Suppl 2: S1979.
  • 26
    Smith DE, Hanna R, Della F, Moore H, Chen H, Farese AM, et al. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 2003; 18: 8796.
  • 27
    Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 1996; 70: 480510.
  • 28
    Reynolds P, Dmitriev I, Curiel D. Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector. Gene Ther 1999; 6: 13369.
  • 29
    Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 970613.
  • 30
    Erbacher P. Methods for adenovirus-mediated gene transfer to airway epithelium. In: RobbinsPD, editor. Methods in molecular medicine, gene therapy protocols. Totowa (NJ): Humana Press; 1997. p. 16984.
  • 31
    Van Beuningen HM, Stoop R, Buma P, Takahashi N, van der Kraan PM, van den Berg WB. Phenotypic differences in murine chondrocyte cell lines derived from mature articular cartilage. Osteoarthritis Cartilage 2002; 10: 97786.
  • 32
    Carlsen H, Moskaug JO, Fromm SH, Blomhoff R. In vivo imaging of NF-κB activity. J Immunol 2002; 168: 14416.
  • 33
    Van de Loo FA, Kuiper S, van Enckevort FH, Arntz OJ, van den Berg WB. Interleukin-6 reduces cartilage destruction during experimental arthritis: a study in interleukin-6-deficient mice. Am J Pathol 1997; 151: 17791.
  • 34
    Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 1569.
  • 35
    Bakker AC, van de Loo FA, Joosten LA, Bennink MB, Arntz OJ, Dmitriev IP, et al. A tropism-modified adenoviral vector increased the effectiveness of gene therapy for arthritis. Gene Ther 2001; 8: 178593.
  • 36
    Korherr C, Hofmeister R, Wesche H, Falk W. A critical role for interleukin-1 receptor accessory protein in interleukin-1 signaling. Eur J Immunol 1997; 27: 2627.
  • 37
    Ju G, Labriola-Tompkins E, Campen CA, Benjamin WR, Karas J, Plocinski J, et al. Conversion of the interleukin 1 receptor antagonist into an agonist by site-specific mutagenesis. Proc Natl Acad Sci U S A 1991; 88: 265862.
  • 38
    Schreuder H, Tardif C, Trump-Kallmeyer S, Soffientini A, Sarubbi E, Akeson A, et al. A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature 1997; 386: 194200.
  • 39
    Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324: 736.
  • 40
    Reed SG, Pihl DL, Conlon PJ, Grabstein KH. IL-1 as adjuvant: role of T cells in the augmentation of specific antibody production by recombinant human IL-1α. J Immunol 1989; 142: 312933.
  • 41
    Staruch MJ, Wood DD. The adjuvanticity of interleukin 1 in vivo. J Immunol 1983; 130: 21914.
  • 42
    Saijo S, Asano M, Horai R, Yamamoto H, Iwakura Y. Suppression of autoimmune arthritis in interleukin-1–deficient mice in which T cell activation is impaired due to low levels of CD40 ligand and OX40 expression on T cells. Arthritis Rheum 2002; 46: 53344.
  • 43
    Nakae S, Asano M, Horai R, Sakaguchi N, Iwakura Y. IL-1 enhances T cell-dependent antibody production through induction of CD40 ligand and OX40 on T cells. J Immunol 2001; 167: 907.
  • 44
    Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci U S A 2003; 100: 598690.
  • 45
    Iwasaki T, Sims JE, Grabstein K, Dower SK, Rachie N, Bomsztyk K. Comparison of IL-1α effectiveness in activating murine pre-B and T cell lines. Cytokine 1993; 5: 41626.
  • 46
    Towne JE, Garka KE, Renshaw BR, Virca GD, Sims JE. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-κB and MAPKs. J Biol Chem 2004; 279: 1367788.
  • 47
    Malinowsky D, Lundkvist J, Laye S, Bartfai T. Interleukin-1 receptor accessory protein interacts with the type II interleukin-1 receptor. FEBS Lett 1998; 429: 299302.